Canine Pipeline
Inflammatory Bowel Disease in Dogs
 |
|---|
| Anti-TNFα Antibody
|
Prevelance
Majority of cases involve chronic states of diarrhea, vomiting, gastroenteritis, and other symptoms. Diarrhea prevalence >5% for certain breeds.
Disease Burden
This is a chronic condition and diagnosed commonly in middle aged dogs. Existing treatments can have significant drawbacks which lead to lapses in treatment and/or poor quality of life in dogs.
Cost Burden
High willingness to pay for treatments given the impact on owner.
Recent Catalyst
Positive results from pilot field effectiveness study. Complete remission, defined as ≥ 75% reduction in average post-dose CIBDAI score from baseline, was achieved in 75% of the anti-TNFα group compared to 17% in the placebo group. The treatment effect was early-onset and durable.
US-CORP-1900168 FEB-20
News
- Elanco Announces Agreement to Acquire Kindred BiosciencesJune 16, 2021 - 6:57 am
- Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by ParvovirusJune 2, 2021 - 8:45 am
- Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XIMay 25, 2021 - 8:57 am
Events
- Event: Kindred Biosciences to Present at the LD Micro Invitational XIMay 25, 2021 - 9:14 am
- Event: Kindred Biosciences to Present at the Stifel 2021 Virtual Jaws & Paws ConferenceMay 25, 2021 - 9:12 am
- Event: Kindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial ResultsMarch 8, 2021 - 8:48 am